FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, and concerns using anti-CD40-antibodies in a combination with CHOP for treating diseases or conditions associated with neoplastic B cell growth, wherein the above disease or condition is resistant to a therapy using (i) CHOP, (ii) a chimeric monoclonal anti-CD20-antibody of rituximab or (iii) CHOP and rituximab in the form of the combination therapy, or a patient has shown recurrence following the therapy using (i) CHOP, (ii) the chimeric monoclonal anti-CD20-antibody of rituximab or (iii) CHOP and rituximab in the form of the combination therapy.
EFFECT: group of inventions provides synergistic therapeutic action ensured by using the combination according to the invention.
26 cl, 4 ex, 6 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF ANTI-CD40-ANTIBODIES | 2006 |
|
RU2442606C2 |
| COMBINATION OF ANTI-EDb FIBRONECTIN ANTIBODY-IL-2 FUSION PROTEIN, AND MOLECULE BINDING TO B-CELLS, B-CELL PROGENITORS AND/OR THEIR CANCEROUS COUNTERPART | 2008 |
|
RU2484845C2 |
| ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION | 2012 |
|
RU2609647C2 |
| METHOD OF TREATING VASCULITIS | 2005 |
|
RU2411956C2 |
| ANTIBODIES TO CD40 FOR USE IN THE TREATMENT OF SJOGREN'S SYNDROME | 2018 |
|
RU2790558C2 |
| CONJUGATES "CALIHEAMICIN DERIVATIVE-CARRIER" | 2003 |
|
RU2422157C2 |
| HUMANISED ANTI-CD40-ANTIBODIES AND METHODS OF APPLICATION THEREOF | 2006 |
|
RU2407544C2 |
| PURIFICATION OF ANTIBODIES WITH CATION-EXCHANGE CHROMATOGRAPHY | 2008 |
|
RU2498991C2 |
| ANTI-CD40-ANTIBODIES, APPLICATION AND METHODS | 2012 |
|
RU2649055C2 |
| METHOD OF TREATING MULTIPLE SCLEROSIS | 2005 |
|
RU2384345C2 |
